ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag industry cancer regulation fda

Q&A: From FDA to Industry
Kerry Grens | Sep 27, 2016 | 5 min read
Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.
Picking Up the Pace
Kate Yandell | Jan 1, 2016 | 10 min read
FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.
april 2019 editorial the scientist
Miracle Elixirs
Bob Grant | Apr 1, 2019 | 3 min read
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
FDA Gives Nod to Melanoma Drug
Jef Akst | Sep 8, 2014 | 2 min read
The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Research laboratory, no people, clean white, horizontal
Making Sense of Regulations
Cytiva | Feb 23, 2023 | 3 min read
Knowing what to focus on, what resources are available, and who to talk to for regulatory advice ahead of time can smooth the drug discovery journey.
A vet and technician take a sample from a dog for use in PetDx’s OncoK9 test, which screens cell-free DNA for genomic alterations associated with cancer.
The Pet Health Industry Takes on Canine Cancer
Diana Kwon | Oct 17, 2022 | 9 min read
Advanced genomic tools have provided biotech companies new approaches to help our furry friends—but experts say several limitations remain.
FDA Actions, Economy Affect Biotech Industry
Peg Brickley | Jul 8, 2001 | 4 min read
Increased scrutiny by federal drug regulators and continued mergers and acquisitions activity could curb expansion in biotechnology and pharmaceutical industries, according to analysts and economists. A capacity constraint caused by a shortage of manufacturing facilities also could chill the overheated biotech market and job growth as companies exhaust their three-year funding cycles in the next few years, cautions Robert Toth, portfolio manager of the medical technology fund of EGM Capital in S
Industry Applauds FDA Plan For Faster Cancer-Drug Review
Steven Benowitz | Apr 28, 1996 | 8 min read
Review But many critics are urging still other changes, including easier approval of 'off-label' uses DÉJÀ VU: NCI's David Parkinson sees parallels with AIDS drug testing. By Oncologists, industry officials, and cancer-patient advocacy organizations are applauding recently announced policy changes at the Food and Drug Administration (FDA) that speed up the approval process for cancer drugs. The plan, announced on March 29 by President Bill Clinton, aims to immediately streamlin

Run a Search

ADVERTISEMENT